Evidence map›Paper›PMID 41530409›Full record

ArticleScientific reports2026

Prevalence and clinical significance of guideline-directed medical therapy in acute heart failure with reduced or mildly reduced ejection fraction.

Yutaro Miyoshi, Takao Kato, Takeshi Morimoto, Neiko Ozasa, Hidenori Yaku, Yasutaka Inuzuka, Yodo Tamaki, Erika Yamamoto, Yusuke Yoshikawa, Takeshi Kitai and 10 more

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Yutaro MiyoshiDepartment of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, Japan.
Takao KatoDepartment of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, Japan. tkato75@kuhp.kyoto-u.ac.jp.
Takeshi MorimotoClinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan.
Neiko OzasaDepartment of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, Japan.
Hidenori YakuDepartment of Cardiology, Northwestern University, Evanston, IL, USA.
Yasutaka InuzukaCardiovascular Medicine, Shiga General Hospital, Moriyama, Japan.
Yodo TamakiDivision of Cardiology, Tenri Hospital, Nara, Japan.
Erika YamamotoDepartment of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, Japan.
Yusuke YoshikawaDepartment of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, Japan.
Takeshi KitaiDepartment of Heart Failure and Transplantation, National Cerebral and Cardiovascular Center, Osaka, Japan.
Moritake IguchiDepartment of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Kazuya NagaoDepartment of Cardiology, Osaka Red Cross Hospital, Osaka, Japan.
Yuichi KawaseDepartment of Cardiology, Kurashiki Central Hospital, Okayama, Japan.
Takashi MorinagaDepartment of Cardiology, Kokura Memorial Hospital, Fukuoka, Japan.
Yutaka FurukawaDepartment of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Hyogo, Japan.
Kenji AndoDepartment of Cardiology, Kokura Memorial Hospital, Fukuoka, Japan.
Yukihito SatoDepartment of Cardiology, Hyogo Prefectural Amagasaki General Medical Center, Hyogo, Japan.
Koichiro KuwaharaDepartment of Cardiovascular Medicine, Shinshu University Graduate School of Medicine, Nagano, Japan.
Koh OnoDepartment of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, Japan.
Takeshi KimuraDepartment of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, Japan.

Funding

Japan Agency for Medical Research and Development 18059186
6 · The paper itself

Abstract

There are limited reports on the prevalence and clinical significance of guideline-directed medical therapy (GDMT) initiation in patients with acute heart failure (HF). We analyzed 2086 patients with acute heart failure with reduced or mildly reduced ejection fraction (HFrEF or HFmrEF) in the KCHF registry. The patients were classified according to the number of GDMT classes at discharge. The primary outcome was a composite of all-cause death or HF hospitalization. There were 181 (8.7%), 508 (24.4%), 791 (37.9%), and 606 (29.1%) patients with GDMT = 0, 1, 2, and 3, respectively. Current smoker, ambulatory status, and HFrEF were associated with full GDMT, whereas age ≥ 80 years old, acute coronary syndrome, anemia, and eGFR < 30 mL/min/1.73m2 were associated with absence of full GDMT. The cumulative 1-year incidence of the primary outcome was 56.3%, 40.7%, 31.9%, and 25.1% with GDMT = 0, 1, 2, and 3, respectively. The excess adjusted risk of patients with GDMT = 0 or 1, but not GDMT = 2 relative to those of GDMT = 3 remained significant for the primary outcome (HR 2.16 [1.66–2.82], 1.33 [1.07–1.66], and 1.03 [0.84–1.27]). Collectively, the greater number of GDMT classes at discharge was associated with a lower risk for all-cause death or HF hospitalization in patients with HFrEF or HFmrEF.(200 words)

Indexed as

Heart FailureStroke VolumeAcute DiseaseAgedAged, 80 and overFemaleHospitalizationHumansMaleMiddle AgedPractice Guidelines as TopicPrevalenceRegistriesAngiotensin-converting enzyme inhibitorsAngiotensin receptor blockersBeta-blockersGuideline-directed medical therapyHeart failureMineralocorticoid receptor antagonists

Identifiers

PMID41530409
PMCPMC12876868

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.